"Psychiatrie" . . . "1211-7579" . . "8"^^ . "I, V" . "1"^^ . . "1" . "Volba l\u00E9\u010Dby \u00FAzkostn\u00FDch poruch je dan\u00E1 pacientov\u00FDmi charakteristikami (jako p\u0159edchoz\u00ED odpov\u011B\u010F na l\u00E9\u010Dbu \u010Di kontraindikace), dostate\u010Dn\u00FDm mno\u017Estv\u00EDm dat podporuj\u00EDc\u00EDch jej\u00ED pou\u017Eit\u00ED, pacientov\u00FDmi a l\u00E9ka\u0159ov\u00FDmi preferencemi, m\u00EDstn\u00ED dostupnost\u00ED. Za nedostate\u010Dn\u00FDm zlep\u0161en\u00EDm b\u00FDv\u00E1 v\u011Bt\u0161\u00ED z\u00E1va\u017Enost poruchy, jej\u00ED del\u0161\u00ED trv\u00E1n\u00ED a sou\u010Dasn\u00E1 soci\u00E1ln\u00ED nep\u0159\u00EDze\u0148. M\u00E1me dostatek informac\u00ED o \u00FA\u010Dinnosti l\u00E9k\u016F (hlavn\u011B antidepresiv) a kognitivn\u011B-behavior\u00E1ln\u00ED terapie u \u00FAzkostn\u00FDch poruch. T\u011Blesn\u00E1 aktivita a cvi\u010Den\u00ED maj\u00ED tak\u00E9 pozitivn\u00ED efekt v klinick\u00FDch i neklinick\u00FDch populac\u00EDch. Generalizovan\u00E1 \u00FAzkostn\u00E1 porucha pat\u0159\u00ED mezi nej\u010Dast\u011Bj\u0161\u00ED du\u0161evn\u00ED onemocn\u011Bn\u00ED v prim\u00E1rn\u00ED p\u00E9\u010Di, \u00FArove\u0148 zneschopn\u011Bn\u00ED je stejn\u00E1 jako u deprese. Ze systematick\u00FDch shrnut\u00ED a randomizovan\u00FDch kontrolovan\u00FDch studi\u00ED vypl\u00FDv\u00E1, \u017Ee n\u011Bkter\u00E9 inhibitory zp\u011Btn\u00E9ho vychyt\u00E1v\u00E1n\u00ED serotoninu (SSRI), inhibitor zp\u011Btn\u00E9ho vychyt\u00E1v\u00E1n\u00ED serotoninu a noradrenalinu (SNRI) venlafaxin, n\u011Bkter\u00E9 benzodiazepiny (BZD), imipramin a buspiron jsou v akutn\u00ED l\u00E9\u010Db\u011B \u00FA\u010Dinn\u00E9; dal\u0161\u00EDmi prov\u011B\u0159ovan\u00FDmi l\u00E1tkami jsou nap\u0159\u00EDklad n\u011Bkter\u00E1 antipsychotika, hydroxyzin, pregabalin, agomelatin. Pokra\u010Dovac\u00ED l\u00E9\u010Dba SSRI \u010Di SNRI vede k vy\u0161\u0161\u00EDmu po\u010Dtu zlep\u0161en\u00ED a remis\u00ED v dlouhodob\u00FDch studi\u00EDch." . . . . . "15" . "Treatment of anxiety disorders"@en . "Kosov\u00E1, Ji\u0159ina" . "Volba l\u00E9\u010Dby \u00FAzkostn\u00FDch poruch je dan\u00E1 pacientov\u00FDmi charakteristikami (jako p\u0159edchoz\u00ED odpov\u011B\u010F na l\u00E9\u010Dbu \u010Di kontraindikace), dostate\u010Dn\u00FDm mno\u017Estv\u00EDm dat podporuj\u00EDc\u00EDch jej\u00ED pou\u017Eit\u00ED, pacientov\u00FDmi a l\u00E9ka\u0159ov\u00FDmi preferencemi, m\u00EDstn\u00ED dostupnost\u00ED. Za nedostate\u010Dn\u00FDm zlep\u0161en\u00EDm b\u00FDv\u00E1 v\u011Bt\u0161\u00ED z\u00E1va\u017Enost poruchy, jej\u00ED del\u0161\u00ED trv\u00E1n\u00ED a sou\u010Dasn\u00E1 soci\u00E1ln\u00ED nep\u0159\u00EDze\u0148. M\u00E1me dostatek informac\u00ED o \u00FA\u010Dinnosti l\u00E9k\u016F (hlavn\u011B antidepresiv) a kognitivn\u011B-behavior\u00E1ln\u00ED terapie u \u00FAzkostn\u00FDch poruch. T\u011Blesn\u00E1 aktivita a cvi\u010Den\u00ED maj\u00ED tak\u00E9 pozitivn\u00ED efekt v klinick\u00FDch i neklinick\u00FDch populac\u00EDch. Generalizovan\u00E1 \u00FAzkostn\u00E1 porucha pat\u0159\u00ED mezi nej\u010Dast\u011Bj\u0161\u00ED du\u0161evn\u00ED onemocn\u011Bn\u00ED v prim\u00E1rn\u00ED p\u00E9\u010Di, \u00FArove\u0148 zneschopn\u011Bn\u00ED je stejn\u00E1 jako u deprese. Ze systematick\u00FDch shrnut\u00ED a randomizovan\u00FDch kontrolovan\u00FDch studi\u00ED vypl\u00FDv\u00E1, \u017Ee n\u011Bkter\u00E9 inhibitory zp\u011Btn\u00E9ho vychyt\u00E1v\u00E1n\u00ED serotoninu (SSRI), inhibitor zp\u011Btn\u00E9ho vychyt\u00E1v\u00E1n\u00ED serotoninu a noradrenalinu (SNRI) venlafaxin, n\u011Bkter\u00E9 benzodiazepiny (BZD), imipramin a buspiron jsou v akutn\u00ED l\u00E9\u010Db\u011B \u00FA\u010Dinn\u00E9; dal\u0161\u00EDmi prov\u011B\u0159ovan\u00FDmi l\u00E1tkami jsou nap\u0159\u00EDklad n\u011Bkter\u00E1 antipsychotika, hydroxyzin, pregabalin, agomelatin. Pokra\u010Dovac\u00ED l\u00E9\u010Dba SSRI \u010Di SNRI vede k vy\u0161\u0161\u00EDmu po\u010Dtu zlep\u0161en\u00ED a remis\u00ED v dlouhodob\u00FDch studi\u00EDch."@cs . . . "L\u00E9\u010Dba \u00FAzkostn\u00FDch poruch" . "209209" . . . . "L\u00E9\u010Dba \u00FAzkostn\u00FDch poruch"@cs . . . "L\u00E9\u010Dba \u00FAzkostn\u00FDch poruch" . . "http://www.tigis.cz/images/stories/psychiatrie/2011/01/04_kosova_psych_1-11.pdf" . "Treatment of anxiety disorders"@en . "CZ - \u010Cesk\u00E1 republika" . . . . "L\u00E9\u010Dba \u00FAzkostn\u00FDch poruch"@cs . "RIV/00023752:_____/11:00001160" . "anticonvulsants; antidepressants; antipsychotics; anxiety disorders; anxiolytics; benzodiazepines; cognitive behavioral therapy; generalized anxiety disorder; physical aktivity; SNRI; SSRI; treatment; treatment guidelines; TCA"@en . "RIV/00023752:_____/11:00001160!RIV12-MZ0-00023752" . . . "[A32E5672BD3B]" . "The need for treatment of anxiety disorders is determined by the severity and persistence of symptoms, the presence of comorbid mental disorder or physical illness, the level of disability and impact on social functioning, concomitant medication, and a history of good response to, or poor tolerability of, previous treatment approaches. Choice of treatment is affected by the patients characteristics (such a previous response or contraindications), the evidence base supporting its use, patiens and physicians preference, and the local availability of the respective intervention. Severity, duration of illness and ongoing social adversity were associated with lack of improvement. There is good evidence for the efficacy of medication and cognitive behavioral therapy for anxiety disorders. The physical activity and exercise have also positive effects in both clinical and nonclinical populations. Generalized anxiety disorder is amongst the most common mental disorders in primary care, leading to the disability comparable to that associated with major depression. Systematic reviews and placebo-controlled RCTs indicate that some SSRIs, the SNRI venlafaxine, some benzodiazepines, imipramine, and buspirone are all efficacious in acute treatment; other compounds with proven efficacy include some antipsychotics, hydroxyzine, pregabalin, and agomelatin. Continuing with SSRI or SNRI treatment is associated with an increase in overall response rates in the long term studies."@en . . "1"^^ . . . . . .